RMD 1206
Alternative Names: RMD-1206Latest Information Update: 23 Jan 2026
At a glance
- Originator Remedium Bio
- Class Antihyperglycaemics; Gene therapies; Obesity therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Obesity; Type 2 diabetes mellitus
Most Recent Events
- 12 Nov 2025 Early research in Obesity in USA (SC), before November 2025 (Remedium Bio pipeline, November 2025)
- 12 Nov 2025 Early research in Type 2 diabetes mellitus in USA (SC), before November 2025 (Remedium Bio pipeline, November 2025
- 10 Jun 2022 Remedium Bio and University of Massachusetts enter into a Sponsored Research Agreement to complete preclinical efficacy studies in Type 1 and Type 2 diabetes pipeline candidates